COST enters its May 28 earnings week having done something it hadn't managed since early spring: closed above the Street's mean price target.
The stock added 7.1% over the past five trading days to reach $1,094.32, a move that pulls it roughly 1.7% above the analyst consensus of $1,076.97. That gap matters. Last week's note described COST closing in on that target from below; now it has crossed it, and the pre-earnings setup is correspondingly more charged. The one-month gain runs to 9.4%, and the stock is up roughly 22% year-to-date. Close peers WMT gained 3.0% on the week and ACI climbed 8.0%, so the broader consumer staples trade has been strong — but COST is outpacing the group.
The borrow market offers no resistance to the rally. Availability is essentially unlimited — the lending pool holds shares equivalent to roughly 99 times current short interest, among the loosest conditions of any large-cap retailer. Cost to borrow has fallen 40% over the past week to just 0.27% annualised, a near-record low in the 30-day window. Short interest has edged up 1.6% on the week to 1.53% of free float, but that is a very low absolute level and the direction is barely worth calling a trend. The ORTEX short score of 32.7 — on a 0-100 scale — sits in a range that implies minimal short-seller conviction. Bears are not building meaningful positions ahead of the print.
Options tell a slightly different story. The put/call ratio has climbed to 1.35, now running above its 20-day average of 1.28 and about one standard deviation elevated. That is the highest reading in roughly a month and close to the 52-week peak of 1.40 reached in late April. It is a mild defensive tilt, not outright alarm — but it does suggest options traders are paying for downside protection even as the stock pushes to new highs. The combination of loose borrow and elevated PCR points to a market that is happy to hold the long but wants a hedge in place for May 28.
The Street is becoming more constructive at the margin. Two target raises landed this week alone: UBS lifted its target to $1,275 while maintaining Buy, and Oppenheimer moved to $1,160 on an Outperform. Both moves were issued after the stock's recent run, meaning neither firm is simply chasing the tape with a stale upgrade. The mean target of $1,077 now lags the current price, which creates a nuanced read: bulls still see $1,160–$1,275 as achievable, while the sideline camp — Wells Fargo at $1,000 and DA Davidson also at $1,000 — argues the valuation already prices in the good news. The PE ratio has expanded to 51.3x on the week's move, up roughly 4 points over the past month, and EV/EBITDA runs at 32.2x. The bear case is explicit: a $1,000 target based on 45x projected 2027 EPS, with membership growth rates and slowing traffic as the friction points. The bull case rests on renewal resilience and the structural advantage of a membership model that generates high-margin fee income independent of transaction volume.
Insider activity adds a mild note of caution as context. The most recent trades on record through early April were all sells — CFO Gary Millerchip sold $1.15 million in March, and several EVPs reduced positions in Q1. The 90-day net figure is a positive $7.3 million in value terms, though that reflects the timing of filings more than a clear directional signal from management. None of the trades carry high significance scores, and the pattern looks more consistent with routine plan-based selling than with conviction on either side.
The prior earnings print in March produced a single-day move of just +2.3%, with the five-day follow-through also modest at +2.6%. History suggests COST rarely delivers violent post-earnings moves. What to watch on May 28 is less whether the warehouse model is holding — it demonstrably is — and more whether management's commentary on tariff exposure, membership fee renewal trajectory, and traffic trends in the current macro environment justifies a PE north of 50x. That is the gap the bulls and bears are actually debating.
See the live data behind this article on ORTEX.
Open COST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
